Utrecht Health Seed Fund

Phlox Therapeutics is a biotechnology company focused on developing gene therapies for heart diseases. It works on approaches to alleviate and cure cardiomyopathies and other genetic cardiac conditions by advancing gene therapy and RNA-based therapeutics, with the goal of delivering lifelong benefits to patients and reducing the impact of disease-causing mutations. The company's programs aim to translate genetic insight into therapies that address the root causes of cardiac disorders and offer the potential to halt progression or restore heart function.

Synerkine Pharma is engaged in the development of innovative fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's focus lies in targeting common regulatory mechanisms associated with various forms of chronic pain. Its fusion proteins possess distinctive properties that help normalize pain and inhibit inflammation, thereby offering potential solutions for patients suffering from different pain types. Through its research and development efforts, Synerkine Pharma seeks to provide pharmaceutical products that effectively reduce pain, as demonstrated in multiple pre-clinical models.

Cordys Analytics specializes in AI-driven cardiac diagnostics. It develops an AI-based platform that interprets electrocardiograms (ECGs), enabling healthcare providers to detect heart illnesses more efficiently and affordably. This platform aims to improve cardiac care by offering timely, accurate diagnoses close to patients, reducing the burden on healthcare systems.

Moveshelf is a cloud-based software platform for 3D character animation, motion capture, and movement analysis. It provides a browser-based interface with secure storage, organization, analysis, reporting and collaboration of 3D motion data, accessible on desktop and mobile devices. The platform supports all major motion capture systems and common 3D motion data formats, and offers APIs in Python and Node.js with compatibility for Unity, Unreal, MATLAB, and other tools. It enables professionals to securely share movement data and interactive multimedia reports via simple links or deeper integrations with clinical IT systems. Moveshelf aims to organize, understand, and serve digital human motion data to help animators, technicians, and movement scientists collaborate more effectively and extract insights from motion data.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.

Moveshelf is a cloud-based software platform for 3D character animation, motion capture, and movement analysis. It provides a browser-based interface with secure storage, organization, analysis, reporting and collaboration of 3D motion data, accessible on desktop and mobile devices. The platform supports all major motion capture systems and common 3D motion data formats, and offers APIs in Python and Node.js with compatibility for Unity, Unreal, MATLAB, and other tools. It enables professionals to securely share movement data and interactive multimedia reports via simple links or deeper integrations with clinical IT systems. Moveshelf aims to organize, understand, and serve digital human motion data to help animators, technicians, and movement scientists collaborate more effectively and extract insights from motion data.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.